Large study checks cancer risk in arthritis drug abatacept
NCT ID NCT05413044
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at real-world data from over 140,000 people in Sweden with rheumatoid arthritis or psoriatic arthritis. Researchers tracked how many people developed different types of cancer while taking abatacept or other arthritis drugs. The goal was to better understand the safety of these treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- abatacept
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Institution
Princeton, New Jersey, 08540, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can group learning make biotherapy safer for arthritis patients?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?